Choroidal Rupture

Back

Background

Choroidal ruptures are breaks in the choroid, the Bruch membrane, and the retinal pigment epithelium (RPE) that result from blunt ocular trauma (the most common eye injury).[1]

Choroidal rupture can be secondary to indirect or direct trauma. Cases secondary to direct trauma tend to be located more anteriorly and at the site of impact and parallel to the ora, whereas those secondary to indirect trauma occur posteriorly. These ruptures have a crescent shape and are concentric to the optic disc. Indirect choroidal ruptures are almost 4 times more common than direct ruptures. See the image below.



View Image

A 23-year-old man was in a motor vehicle accident 2 months before his presentation. His visual acuity is 20/400, and an afferent pupillary defect is p....



View Image

Mid-phase fluorescein angiogram in a 23-year-old man who was in a motor vehicle accident 2 months before his presentation. (Courtesy of Jorge Gutierre....



View Image

Late-phase fluorescein angiogram in a 23-year-old who man was in a motor vehicle accident 2 months before his presentation. (Courtesy of Jorge Gutierr....

Pathophysiology

After blunt trauma, the ocular globe undergoes mechanical compression and then sudden hyperextension. Because of its tensile strength, the sclera can resist this insult; the retina is also protected because of its elasticity. The Bruch membrane does not have enough elasticity or tensile strength; therefore, it breaks.

Concurrently, the small capillaries in the choriocapillaris are damaged, leading to subretinal or sub-RPE hemorrhage. Hemorrhage in conjunction with retinal edema may obscure the choroidal rupture during the acute phases. The deep choroidal vessels are usually spared. As the blood clears, a white, curvilinear, crescent-shaped streak concentric to the optic nerve is seen.

During the healing phase, choroidal neovascularization (CNV) occurs. Vascular endothelial growth factor (VEGF) has been shown to be a key molecular player in the pathogenesis of CNV. In most cases, it involutes spontaneously.

In 15-30% of patients, CNV may arise again and lead to a hemorrhagic or serous macular detachment with concomitant visual loss. This usually occurs during the first year but can also occur decades later. If the rupture does not involve the fovea, good vision is expected.

Older age and macular rupture, the length of the rupture, and the distance of the rupture to the center of the fovea may be risk factors for CNV.

Epidemiology

Frequency

United States

Blunt ocular trauma is the most common type of eye injury. Approximately 5-10% of patients with such injury develop a choroidal rupture. Most eyes have a single rupture, but up to 25% of eyes have multiple ruptures. About 80% of ruptures occur temporal to the disc, and 66% involve the macula.

Mortality/Morbidity

Vision loss depends on whether the choroidal rupture involves the fovea and whether and where CNV occurs.

Sex

Men appear to be more prone to ocular trauma than women.

A male-to-female ratio of 5:1 is reported for choroidal ruptures.[2, 3]

Age

In most series, this condition occurs in patients aged 20-40 years.[2, 3]

History

See the list below:

Physical

See the list below:

Causes

See the list below:

Imaging Studies

Because choroidal ruptures occur as a consequence of blunt ocular trauma, the ocular examination must be thorough to rule out orbital fractures or globe ruptures.

CT scanning/MRI

Consider CT scanning and MRI of the eye and orbit under appropriate circumstances.

Fluorescein angiography

Fluorescein angiography may be a useful adjunct to detect CNV.

If CNV is absent, hypofluorescence occurs during the early phase of the angiogram due to disruption of the choriocapillaris. During later stages, hyperfluorescence occurs from the adjacent healthy choriocapillaris.

If CNV is present, early hyperfluorescence followed by late leakage is present on the angiogram.

Angiography

Indocyanine green (ICG) angiography may be useful if subretinal blood blocks or hides CNV detection on a fluorescein angiogram.

Optical coherence tomography

With the advent of anti-VEGF therapy, optical coherence tomography (OCT) plays a major role in the management of CNV. Most clinicians consider the presence of fluid on the OCT scan as an indication of CNV activity and the need for further treatment.

Histologic Findings

Direct choroidal ruptures are characterized by a complete absence of choroid and RPE. The overlying retina is intact but atrophic.

In indirect choroidal ruptures, CNV is a common finding during the early healing phases. Most CNV is in the subretinal space (Gass type 2). With time, most CNV involutes spontaneously. In a small number of cases, a disciform scar or fibrous tissue may grow into the retina and vitreous cavity.

Medical Care

During the healing phase of virtually all choroidal ruptures, CNV is present. CNV may be thought of as part of the wound healing response. Most cases of CNV involute spontaneously. In up to 30% of patients, CNV may arise again and cause visual loss.

Prior to the advent of anti-VEGF therapy, good management options for subfoveal CNV were not really available; therefore, a conservative approach was recommended for most choroidal ruptures.

In the current era of anti-VEGF therapy, the extraordinary results obtained in CNV secondary to age-related macular degeneration have been extrapolated to other causes of CNV with apparent good results.[4, 5]

Currently available anti-VEGF agents include bevacizumab, ranibizumab, pegaptanib sodium, and aflibercept (see Medication).[6, 7]

Surgical Care

If CNV is extrafoveal, it may be treated successfully with laser photocoagulation. Recurrences seem few.[8]

Prior to the advent of anti-VEGF therapy, pars plana vitrectomy with membrane extraction was considered for subfoveal or juxtafoveal CNV.[9]

The role of photodynamic therapy with verteporfin is unclear; however, several case reports and case series using this treatment have shown encouraging results in these patients.

ICG-guided photocoagulation transiently closes feeder vessels of subfoveal CNV, but, eventually, these vessels become reperfused.

Currently, anti-VEGF therapy appears to have the most success.[5, 4]

Consultations

Consult a vitreoretinal specialist.

Ranibizumab (Lucentis)

Clinical Context:  Recombinant humanized IgG1-kappa isotype monoclonal antibody fragment designed for intraocular use. Indicated for neovascular (wet) age-related macular degeneration (ARMD). In clinical trials, about one third of patients had improved vision at 12 mo that was maintained by monthly injections. Binds to VEGF-A, including biologically active, cleaved form (ie, (VEGF110). VEGF-A has been shown to cause neovascularization and leakage in ocular angiogenesis models and is thought to contribute to ARMD disease progression. Binding VEGF-A prevents interaction with its receptors (ie, VEGFR1, VEGFR2) on surface of endothelial cells, thereby reducing endothelial cell proliferation, vascular leakage, and new blood vessel formation.

Pegaptanib (Macugen)

Clinical Context:  Selective vascular endothelial growth factor (VEGF) antagonist that promotes vision stability and reduces visual-acuity loss and progression to legal blindness. VEGF causes angiogenesis and increases vascular permeability and inflammation, all which contribute to neovascularization in age-related wet macular degeneration.

Bevacizumab (Avastin)

Clinical Context:  Murine derived monoclonal antibody that inhibits angiogenesis by targeting and inhibiting vascular endothelial growth factor (VEGF). Used investigationally for ARMD secondary to choroidal neovascularization.

Aflibercept (Eylea)

Clinical Context:  Fusion protein of key domains from human VEGF receptors 1 (VEGFR1) and 2 (VEGFR2) with human IgGFc designed for intraocular use. Indicated for neovascular (wet) age-related macular degeneration (ARMD) and macular edema secondary to central retinal vein occlusion. Binds to VEGF-A, including biologically active, cleaved form (ie, (VEGF110) and placental growth factor. VEGF-A has been shown to cause neovascularization and leakage in ocular angiogenesis models and is thought to contribute to ARMD disease progression. Binding VEGF-A prevents interaction with its receptors (ie, VEGFR1, VEGFR2) on surface of endothelial cells, thereby reducing endothelial cell proliferation, vascular leakage, and new blood vessel formation.

Class Summary

Vascular endothelial growth factor (VEGF) is essential for angiogenesis. Inhibitors of VEGF that bind to the receptor of VEGF-A isoforms prevent its interaction with Flt-1 and KDR on the endothelial cell surface, and therefore decreases cell proliferation and new blood vessel formation.

Further Outpatient Care

Most CNV occurs within the first year. However, CNV has been reported to occur as late as 35 years after the choroidal rupture.

Regularly scheduled examinations with fluorescein angiography (as circumstances dictate) are recommended during the first year.

Deterrence/Prevention

In view of the high risk of sustaining a traumatic choroidal rupture, protective eyewear should be mandatory when participating in paintball.[10, 11]

Complications

In 15-30% of patients, CNV may arise and lead to a hemorrhagic or serous macular detachment with concomitant visual loss.

Prognosis

Most patients with choroidal ruptures do not reach a final visual acuity of 20/40 or better. Poor visual acuity is associated with macular rupture and poor baseline visual acuity.[12]

If the rupture does not involve the fovea, good vision is expected.

A hemorrhagic or serous macular detachment secondary to CNV may threaten visual function.

If CNV is extrafoveal, it may respond well to laser photocoagulation. Few recurrences are reported after laser photocoagulation.

Bevacizumab is a humanized recombinant monoclonal IgG antibody that binds and inhibits all VEGF isoforms. A few series have reported beneficial results following intravitreal bevacizumab.[4, 5]

If CNV is juxtafoveal or subfoveal, consider pars plana vitrectomy with membrane extraction. Gross et al reported good visual acuities in a small case series.[9]

Patient Education

Teach patients to self-monitor each eye by using an Amsler grid and a near card.

Author

Lihteh Wu, MD, Ophthalmologist, Costa Rica Vitreo and Retina Macular Associates

Disclosure: Received income in an amount equal to or greater than $250 from: Bayer Health; Quantel Medical.

Coauthor(s)

Dhariana Acón, MD, Ophthalmologist, Caja Costarricense Seguro Social, Hospital de Guapiles, Costa Rica

Disclosure: Nothing to disclose.

Specialty Editors

Simon K Law, MD, PharmD, Clinical Professor of Health Sciences, Department of Ophthalmology, Jules Stein Eye Institute, University of California, Los Angeles, David Geffen School of Medicine

Disclosure: Nothing to disclose.

Steve Charles, MD, Founder and CEO of Charles Retina Institute; Clinical Professor, Department of Ophthalmology, University of Tennessee College of Medicine

Disclosure: Received royalty and consulting fees for: Alcon Laboratories.

Chief Editor

Hampton Roy, Sr, MD, Associate Clinical Professor, Department of Ophthalmology, University of Arkansas for Medical Sciences

Disclosure: Nothing to disclose.

Additional Contributors

Russell P Jayne, MD, Vitreoretinal Surgeon, The Retina Center at Las Vegas

Disclosure: Nothing to disclose.

Acknowledgements

Teodoro Evans, MD Consulting Surgeon, Vitreo-Retinal Section, Clinica de Ojos, Costa Rica

Disclosure: Nothing to disclose.

References

  1. Sponsel WE, Gray W, Scribbick FW, Stern AR, Weiss CE, Groth SL, et al. Blunt eye trauma: empirical histopathologic paintball impact thresholds in fresh mounted porcine eyes. Invest Ophthalmol Vis Sci. 2011 Jul. 52(8):5157-66. [View Abstract]
  2. Liggett PE, Pince KJ, Barlow W, Ragen M, Ryan SJ. Ocular trauma in an urban population. Review of 1132 cases. Ophthalmology. 1990 May. 97(5):581-4. [View Abstract]
  3. White MF Jr, Morris R, Feist RM, Witherspoon CD, Helms HA Jr, John GR. Eye injury: prevalence and prognosis by setting. South Med J. 1989 Feb. 82(2):151-8. [View Abstract]
  4. Yadav NK, Bharghav M, Vasudha K, Shetty KB. Choroidal neovascular membrane complicating traumatic choroidal rupture managed by intravitreal bevacizumab. Eye (Lond). 2009 Sep. 23(9):1872-3. [View Abstract]
  5. Chanana B, Azad RV, Kumar N. Intravitreal bevacizumab for subfoveal choroidal neovascularization secondary to traumatic choroidal rupture. Eye. 2009 Jan 23. [View Abstract]
  6. Piermarocchi S, Benetti E, Fracasso G. Intravitreal bevacizumab for posttraumatic choroidal neovascularization in a child. J AAPOS. 2011 Jun. 15(3):314-6. [View Abstract]
  7. Heier JS, Brown DM, Chong V, Korobelnik JF, Kaiser PK, Nguyen QD. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology. 2012 Dec. 119(12):2537-48. [View Abstract]
  8. Fuller B, Gitter KA. Traumatic choroidal rupture with late serous detachment of macula. Report of successful argon laser treatment. Arch Ophthalmol. 1973 Apr. 89(4):354-5. [View Abstract]
  9. Gross JG, King LP, de Juan E Jr, Powers T. Subfoveal neovascular membrane removal in patients with traumatic choroidal rupture. Ophthalmology. 1996 Apr. 103(4):579-85. [View Abstract]
  10. Baath J, Ells AL, Kherani A, Williams RG. Severe retinal injuries from paintball projectiles. Can J Ophthalmol. 2007 Aug. 42(4):620-3. [View Abstract]
  11. Pahk PJ, Adelman RA. Ocular trauma resulting from paintball injury. Graefes Arch Clin Exp Ophthalmol. 2009 Apr. 247(4):469-75. [View Abstract]
  12. Ament CS, Zacks DN, Lane AM, et al. Predictors of visual outcome and choroidal neovascular membrane formation after traumatic choroidal rupture. Arch Ophthalmol. 2006 Jul. 124(7):957-66. [View Abstract]
  13. Aguilar JP, Green WR. Choroidal rupture. A histopathologic study of 47 cases. Retina. 1984 Fall-Winter. 4(4):269-75. [View Abstract]
  14. Bellows JG. Observations on 300 cases of ocular war injuries. Am J Ophthalmol. 1947. 30:309-323.
  15. Conrath J, Forzano O, Ridings B. Photodynamic therapy for subfoveal CNV complicating traumatic choroidal rupture. Eye (Lond). 2004 Sep. 18(9):946-7. [View Abstract]
  16. Eagling EM. Ocular damage after blunt trauma to the eye. Its relationship to the nature of the injury. Br J Ophthalmol. 1974 Feb. 58(2):126-40. [View Abstract]
  17. Harissi-Dagher M, Sebag M, Gauthier D, Marcil G, Labelle P, Arbour JD. Photodynamic therapy in young patients with choroidal neovascularization following traumatic choroidal rupture. Am J Ophthalmol. 2005 Apr. 139(4):726-8. [View Abstract]
  18. Hart JC, Natsikos VE, Raistrick ER, Doran RM. Indirect choroidal tears at the posterior pole: a fluorescein angiographic and perimetric study. Br J Ophthalmol. 1980 Jan. 64(1):59-67. [View Abstract]
  19. Hilton GF. Late serosanguineous detachment of the macula after traumatic choroidal rupture. Am J Ophthalmol. 1975 Jun. 79(6):997-1000. [View Abstract]
  20. Leys A, Dralands L, Missotten L. Late complications of choroidal ruptures. Bull Soc Belge Ophtalmol. 1981. 193:137-41. [View Abstract]
  21. Luxenberg MN. Subretinal neovascularization associated with rupture of the choroid. Arch Ophthalmol. 1986 Aug. 104(8):1233. [View Abstract]
  22. Mehta HB, Shanmugam MP. Photodynamic therapy of a posttraumatic choroidal neovascular membrane. Indian J Ophthalmol. 2005 Jun. 53(2):131-2. [View Abstract]
  23. Mennel S, Hausmann N, Meyer CH, Peter S. Photodynamic therapy and indocyanine green guided feeder vessel photocoagulation of choroidal neovascularization secondary to choroid rupture after blunt trauma. Graefes Arch Clin Exp Ophthalmol. 2005 Jan. 243(1):68-71. [View Abstract]
  24. Pearlstone AD. Delayed loss of central vision following multiple posterior segment trauma. Ann Ophthalmol. 1980 Apr. 12(4):409-11. [View Abstract]
  25. Secretan M, Sickenberg M, Zografos L, Piguet B. Morphometric characteristics of traumatic choroidal ruptures associated with neovascularization. Retina. 1998. 18(1):62-6. [View Abstract]
  26. Smith RE, Kelley JS, Harbin TS. Late macular complications of choroidal ruptures. Am J Ophthalmol. 1974 May. 77(5):650-8. [View Abstract]
  27. Von Graefe A. Zwei falle von ruptur der choroida. Graefes. Arch Clin Exp Ophthalmol. 1854. 1:402.
  28. Wood CM, Richardson J. Chorioretinal neovascular membranes complicating contusional eye injuries with indirect choroidal ruptures. Br J Ophthalmol. 1990 Feb. 74(2):93-6. [View Abstract]
  29. Wyszynski RE, Grossniklaus HE, Frank KE. Indirect choroidal rupture secondary to blunt ocular trauma. A review of eight eyes. Retina. 1988. 8(4):237-43. [View Abstract]

A 23-year-old man was in a motor vehicle accident 2 months before his presentation. His visual acuity is 20/400, and an afferent pupillary defect is present. Traumatic optic neuropathy and choroidal rupture are observed. This is a red-free photograph. (Courtesy of Jorge Gutierrez, MD.)

Mid-phase fluorescein angiogram in a 23-year-old man who was in a motor vehicle accident 2 months before his presentation. (Courtesy of Jorge Gutierrez, MD.)

Late-phase fluorescein angiogram in a 23-year-old who man was in a motor vehicle accident 2 months before his presentation. (Courtesy of Jorge Gutierrez, MD.)

A 23-year-old man was in a motor vehicle accident 2 months before his presentation. His visual acuity is 20/400, and an afferent pupillary defect is present. Traumatic optic neuropathy and choroidal rupture are observed. This is a red-free photograph. (Courtesy of Jorge Gutierrez, MD.)

Mid-phase fluorescein angiogram in a 23-year-old man who was in a motor vehicle accident 2 months before his presentation. (Courtesy of Jorge Gutierrez, MD.)

Late-phase fluorescein angiogram in a 23-year-old who man was in a motor vehicle accident 2 months before his presentation. (Courtesy of Jorge Gutierrez, MD.)